利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

13534 records (took 0.044 seconds)

    COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS
    92.
    发明公开
    COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS 审中-公开

    公开(公告)号：US20240109957A1

    公开(公告)日：2024-04-04

    申请号：US17769180

    申请日：2020-10-16

    Applicant: Annexon, Inc.

    Inventor： Ted Yednock ,  Sethu Sankaranarayanan

    IPC: C07K16/18 ,  A61P7/00

    CPC classification number: C07K16/18 ,  A61P7/00 ,  A61K2039/545 ,  C07K2317/55

    Abstract: The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, antiphospholipid syndrome, Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SLE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.

    THERAPEUTIC SINGLE DOMAIN ANTIBODY
    96.
    发明公开
    THERAPEUTIC SINGLE DOMAIN ANTIBODY 审中-公开

    公开(公告)号：US20240101652A1

    公开(公告)日：2024-03-28

    申请号：US17822642

    申请日：2022-08-26

    Applicant: Singh Biotechnology, LLC

    Inventor： Sunanda Singh

    IPC: C07K16/18 ,  A61P35/00

    CPC classification number: C07K16/18 ,  A61P35/00 ,  C07K2317/569 ,  C07K2317/82

    Abstract: This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer.

    Antibody Delivery
    97.
    发明公开
    Antibody Delivery 审中-公开

    公开(公告)号：US20240100187A1

    公开(公告)日：2024-03-28

    申请号：US18039840

    申请日：2021-12-17

    Applicant: AC Immune SA

    Inventor： Gregorio Del Val ,  Damien Névoltris

    IPC: A61K48/00 ,  C07K16/18 ,  C12N15/86

    CPC classification number: A61K48/0058 ,  A61K48/0066 ,  C07K16/18 ,  C12N15/86 ,  C07K2317/622 ,  C12N2750/14143

    Abstract: A vector comprises a polynucleotide encoding an antibody or antibody fragment for use in a method of treatment of a disease or disorder of the central nervous system (CNS) in a subject, wherein the vector transduces or transfects cells of the blood brain barrier (BBB) and the transduced or transfected BBB cells express the antibody or antibody fragment resulting in delivery of the antibody or antibody fragment into the CNS, preferably into the brain parenchyma. Expression cassettes useful in such vectors may comprise from 5′ to 3′: at least one promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and to a second gene encoding a heavy chain of the antibody or antibody fragment and further comprise an IRES after the first gene encoding the light chain of the antibody or antibody fragment and before the second gene encoding the heavy chain of the antibody or antibody fragment or a first promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and a second promoter operably linked to a second gene encoding a heavy chain of the antibody or antibody fragment. The antibodies and antibody fragments thus produced may be of higher quality, displaying lower levels of aggregation and unwanted immunogenicity.

Patent Agency Ranking